DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling

Nature Medicine

Volumn 22, Issue 12, 2016, Pages 1488-1495

  Guryanova, Olga A ^a   Shank, Kaitlyn ^a   Spitzer, Barbara ^a   Luciani, Luisa ^b   Koche, Richard P ^a   Garrett Bakelman, Francine E ^c   Ganzel, Chezi ^d   Durham, Benjamin H ^a   Mohanty, Abhinita ^a   Hoermann, Gregor ^e   Rivera, Sharon A ^f   Chramiec, Alan G ^a   Pronier, Elodie ^a   Bastian, Lennart ^a   Keller, Matthew D ^a   Tovbin, Daniel ^a   Loizou, Evangelia ^a   Weinstein, Abby R ^a   Gonzalez, Adriana Rodriguez ^a   Lieu, Yen K ^f   Rowe, Jacob M ^d   Pastore, Friederike ^a   McKenney, Anna Sophia ^a   Krivtsov, Andrei V ^a   Sperr, Wolfgang R ^e   Cross, Justin R ^a   Mason, Christopher E ^c   Tallman, Martin S ^a   Arcila, Maria E ^a   Abdel Wahab, Omar ^a   Armstrong, Scott A ^a   Kubicek, Stefan ^g   Staber, Philipp B ^e   Gönen, Mithat ^a   Paietta, Elisabeth M ^h   Melnick, Ari M ^c   Nimer, Stephen D ^b   Mukherjee, Siddhartha ^f   Levine, Ross L ^a   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d SHAARE ZEDEK MEDICAL CENTER   (Israel)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f Och Spine at New York Presbyterian Hospitals   (United States)

^g ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^h MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACLARUBICIN; ANTHRACYCLINE; ATR PROTEIN; BLEOMYCIN; CASPASE 3; CD135 ANTIGEN; CHAPERONE; CHECKPOINT KINASE 2; DAUNORUBICIN; DNA METHYLTRANSFERASE 3A; DOXORUBICIN; ETOPOSIDE; HISTONE H2A; HISTONE H2AX; HISTONE H2B; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; MESSENGER RNA; MITOMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NUCLEOPHOSMIN; PROTEIN P53; SPT 16 PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DNA (CYTOSINE 5) METHYLTRANSFERASE; NUCLEAR PROTEIN; NUCLEOSOME;

ACUTE MYELOBLASTIC LEUKEMIA; ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RESISTANCE; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; HEMATOPOIETIC STEM CELL; INDUCTION CHEMOTHERAPY; MECHANICAL TORSION; MINIMAL RESIDUAL DISEASE; MOUSE; MUTAGENESIS; MYELOBLAST; NONHUMAN; NUCLEOSOME; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SOMATIC MUTATION; ANIMAL; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE; GENETICS; HUMAN; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LEUKEMIA, MYELOID, ACUTE; MASS SPECTROMETRY; METABOLISM; MUTATION; TUMOR CELL LINE;

ANIMALS; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHROMATIN ASSEMBLY AND DISASSEMBLY; DAUNORUBICIN; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DRUG RESISTANCE, NEOPLASM; FMS-LIKE TYROSINE KINASE 3; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LEUKEMIA, MYELOID, ACUTE; MASS SPECTROMETRY; MICE; MUTATION; NUCLEAR PROTEINS; NUCLEOSOMES;

EID: 84995487964     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4210     Document Type: Article

References (52)

1. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059-2074 (2013).
2. Ley, T. J. et al. DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med. 363, 2424-2433 (2010).
3. Yan, X. J. et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat. Genet. 43, 309-315 (2011).
4. Genovese, G. et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N. Engl. J. Med. 371, 2477-2487 (2014).
5. Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371, 2488-2498 (2014).
6. Patel, J. P. et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N. Engl. J. Med. 366, 1079-1089 (2012).
7. Sehgal, A. R. et al. DNMT3A mutational status affects the results of dose-escalated induction therapy in acute myelogenous leukemia. Clin. Cancer Res. 21, 1614-1620 (2015).
8. Shlush, L. I. et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 506, 328-333 (2014).
9. Leiserson, M. D. et al. Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nat. Genet. 47, 106-114 (2015).
10. Welch, J. S. et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 150, 264-278 (2012).
11. Busque, L. et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat. Genet. 44, 1179-1181 (2012).
12. Jan, M. et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci. Transl. Med. 4, 149ra118 (2012).
13. Challen, G. A. et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat. Genet. 44, 23-31 (2011).
14. Moran-Crusio, K. et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 20, 11-24 (2011).
15. Quivoron, C. et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 20, 25-38 (2011).
16. Li, Z. et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 118, 4509-4518 (2011).
17. Yang, L., Rau, R., Goodell, M. A. DNMT3A in haematological malignancies. Nat. Rev. Cancer 15, 152-165 (2015).
18. Holz-Schietinger, C., Matje, D. M., Reich, N. O. Mutations in DNA methyltransferase (DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation. J. Biol. Chem. 287, 30941-30951 (2012).
19. Russler-Germain, D. A. et al. The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell 25, 442-454 (2014).
20. Kim, S. J. et al. A DNMT3A mutation common in AML exhibits dominant-negative effects in murine ES cells. Blood 122, 4086-4089 (2013).
21. Papaemmanuil, E. et al. Genomic classification and prognosis in acute myeloid leukemia. N. Engl. J. Med. 374, 2209-2221 (2016).
22. Gaidzik, V. I. et al. Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). Blood 121, 4769-4777 (2013).
23. Ostronoff, F. et al. Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report. Leukemia 27, 238-241 (2013).
24. Ribeiro, A. F. et al. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Blood 119, 5824-5831 (2012).
25. Tie, R. et al. Association between DNMT3A mutations and prognosis of adults with de novo acute myeloid leukemia: a systematic review and meta-analysis. PLoS One 9, e93353 (2014).
26. Chen, X. et al. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. J. Clin. Oncol. 33, 1258-1264 (2015).
27. Ganzel, C. et al. Minimal residual disease assessment by flow cytometry in AML is an independent prognostic factor even after adjusting for cytogenetic/molecular abnormalities. Blood 124, 1016 (2014).
28. Ivey, A. et al. Assessment of minimal residual disease in standard-risk AML. N. Engl. J. Med. 374, 422-433 (2016).
29. Othus, M. et al. Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia. Leukemia 30, 2080-2083 (2016).
30. Walter, R. B. et al. Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. Leukemia 29, 137-144 (2015).
31. Shih, A. H. et al. Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia. Cancer Cell 27, 502-515 (2015).
32. Akalin, A. et al. Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia. PLoS Genet. 8, e1002781 (2012).
33. Garrett-Bakelman, F. E. et al. Enhanced reduced representation bisulfite sequencing for assessment of DNA methylation at base pair resolution. J. Vis. Exp. http://dx. doi. org/10. 3791/52246, e52246 (2015).
34. Yang, F., Teves, S. S., Kemp, C. J., Henikoff, S. Doxorubicin, DNA torsion, chromatin dynamics. Biochim. Biophys. Acta 1845, 84-89 (2014).
35. Stracker, T. H., Usui, T., Petrini, J. H. Taking the time to make important decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage response. DNA Repair (Amst. ) 8, 1047-1054 (2009).
36. Collins, A. R. et al. The comet assay: topical issues. Mutagenesis 23, 143-151 (2008).
37. Pang, B. et al. Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nat. Commun. 4, 1908 (2013).
38. Dinant, C. et al. Enhanced chromatin dynamics by FACT promotes transcriptional restart after UV-induced DNA damage. Mol. Cell 51, 469-479 (2013).
39. Ransom, M., Dennehey, B. K., Tyler, J. K. Chaperoning histones during DNA replication and repair. Cell 140, 183-195 (2010).
40. Belotserkovskaya, R. et al. FACT facilitates transcription-dependent nucleosome alteration. Science 301, 1090-1093 (2003).
41. Mayle, A., Luo, M., Jeong, M., Goodell, M. A. Flow cytometry analysis of murine hematopoietic stem cells. Cytometry A 83, 27-37 (2013).
42. Akashi, K., Traver, D., Miyamoto, T., Weissman, I. L. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 404, 193-197 (2000).
43. Chen, K. et al. Resolving the distinct stages in erythroid differentiation based on dynamic changes in membrane protein expression during erythropoiesis. Proc. Natl. Acad. Sci. USA 106, 17413-17418 (2009).
44. Socolovsky, M. et al. Ineffective erythropoiesis in Stat5a/5b/mice due to decreased survival of early erythroblasts. Blood 98, 3261-3273 (2001).
45. Paietta, E. Should minimal residual disease guide therapy in AML Best Pract. Res. Clin. Haematol. 28, 98-105 006 (2015).
46. Paietta, E. Minimal residual disease in acute myeloid leukemia: coming of age. Hematology (Am Soc Hematol Educ Program) 2012, 35-42 (2012).
47. Cheng, D. T. et al. Memorial Sloan Kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): A hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J. Mol. Diagn. 17, 251-264 (2015).
48. Nguyen, S., Meletis, K., Fu, D., Jhaveri, S., Jaenisch, R. Ablation of de novo DNA methyltransferase Dnmt3a in the nervous system leads to neuromuscular defects and shortened lifespan. Dev. Dyn. 236, 1663-1676 (2007).
49. Havre, P. A., Yuan, J., Hedrick, L., Cho, K. R., Glazer, P. M. p53 inactivation by HPV16 E6 results in increased mutagenesis in human cells. Cancer Res. 55, 4420-4424 (1995).
50. Whitfield, M. L. et al. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol. Biol. Cell 13, 1977-2000 (2002).
51. Wysocka, J. Identifying novel proteins recognizing histone modifications using peptide pull-down assay. Methods 40, 339-343 (2006).
52. Westfall, P. H., Young, S. S. P-value adjustments for multiple tests in multivariate binomial models. J. Am. Stat. Assoc. 84, 780-786 (1989).